“My cough was really so deep that it felt like I broke my ribs, and my ribs became so cramped that I couldn’t even twist [my body].”

Voice of the Patient Report: “Idiopathic Pulmonary Fibrosis”, March 2015.

“My cough was really so deep that it felt like I broke my ribs, and my ribs became so cramped that I couldn’t even twist [my body].”

Voice of the Patient Report: “Idiopathic Pulmonary Fibrosis”, March 2015.

Haduvio and Chronic Cough

Chronic cough impacts up to 10% of the adult population and has physical, psychological, and social impacts on patients’ lives. We are investigating the use of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The chronic cough these patients experience is highly disruptive and accompanied by a wide range of complications, which causes a significant burden on patients, caregivers, and healthcare systems. Currently, there are no approved therapies in the U.S. for these conditions. 

The cause of chronic cough is believed to be the result of a hypersensitivity disorder in the central and peripheral nerves. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that we believe play a key role in controlling chronic cough. In 2025, we announced positive results from our Phase 2b CORAL trial in patients with IPF chronic cough and from our Phase 2a RIVER trial in patients with RCC. Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC.